The efficacy and safety of methotrexate and intermittent cyclosporine therapy in extensive chronic plaque psoriasis: A randomized, double-blind, and comparative study

Suchibrata Das; Sangita Patra; Saikat Banerjee; Alok Kumar Roy

doi:10.5455/njppp.2023.13.04171202312052023

2026, Vol: 16, Issue: 2

16 / 2Current Issue Online First Archive Aims and Scope Abstracting & Indexing Most Accessed Articles Most Downloaded Articles Most Cited Articles

Required files to be uploaded

NJPPP Manuscript Submission Form
Title Page

« Previous Article

Original Research
Online Published: 29 May 2023

Natl J Physiol Pharm Pharmacol. 2023; 13(12): 2433-2439

doi: 10.5455/njppp.2023.13.04171202312052023

The efficacy and safety of methotrexate and intermittent cyclosporine therapy in extensive chronic plaque psoriasis: A randomized, double-blind, and comparative study

Suchibrata Das, Sangita Patra, Saikat Banerjee, Alok Kumar Roy.

Abstract
Background: Psoriasis vulgaris is common papulosquamous disorder. Methotrexate (MTX) and cyclosporine, both of these drugs are in regular use for psoriasis management. But which one is superior in efficacy are yet to establish.

Aims and Objectives: The aim of the study was to compare efficacy of MTX and intermittent cyclosporine therapy in the management of extensive/severe psoriasis, and to find and compare the incidence of adverse effects/safety of both the drugs.

Materials and Methods: A randomized and controlled study was designed to compare the efficacy and safety of treatment. Patients with extensive psoriasis were randomly put in two groups –MTX and cyclosporine group and treated for 12 weeks.

Results: Psoriasis area severity index (PASI) gradually reduced in both group, that is, up to second visit of study, (4 Weeks after induction of study) the reduction was at par. After that, it reduced in Cyclosporine group significantly faster than MTX group. At the end of the study, that is, after 12 weeks, the difference of PASI in both groups was not significant.
Side-effects were not serious and minimal.

Conclusion: Both the drugs are effective, but Cyclosporine is faster in onset than MTX. Adverse effects are nominal and not serious.

Key words: Psoriasis; Methotrexate; Intermittent Cyclosporine; Efficacy; Adverse Effects

	ARTICLE TOOLS
	Abstract
	PDF Fulltext
	How to cite this article
	Citation Tools
	Related Records
	Articles by Suchibrata Das Articles by Sangita Patra Articles by Saikat Banerjee Articles by Alok Kumar Roy
	on Google
	on Google Scholar

How to Cite this Article

Pubmed Style

Das S, Patra S, Banerjee S, Roy AK. The efficacy and safety of methotrexate and intermittent cyclosporine therapy in extensive chronic plaque psoriasis: A randomized, double-blind, and comparative study. Natl J Physiol Pharm Pharmacol. 2023; 13(12): 2433-2439.

doi:10.5455/njppp.2023.13.04171202312052023

Web Style

Das S, Patra S, Banerjee S, Roy AK. The efficacy and safety of methotrexate and intermittent cyclosporine therapy in extensive chronic plaque psoriasis: A randomized, double-blind, and comparative study. https://www.njppp.com/?mno=148286 [Access: June 27, 2026].

doi:10.5455/njppp.2023.13.04171202312052023

AMA (American Medical Association) Style

Das S, Patra S, Banerjee S, Roy AK. The efficacy and safety of methotrexate and intermittent cyclosporine therapy in extensive chronic plaque psoriasis: A randomized, double-blind, and comparative study. Natl J Physiol Pharm Pharmacol. 2023; 13(12): 2433-2439.

doi:10.5455/njppp.2023.13.04171202312052023

Vancouver/ICMJE Style

Das S, Patra S, Banerjee S, Roy AK. The efficacy and safety of methotrexate and intermittent cyclosporine therapy in extensive chronic plaque psoriasis: A randomized, double-blind, and comparative study. Natl J Physiol Pharm Pharmacol. (2023), [cited June 27, 2026]; 13(12): 2433-2439.

doi:10.5455/njppp.2023.13.04171202312052023

Harvard Style

Das, S., Patra, . S., Banerjee, . S. & Roy, . A. K. (2023) The efficacy and safety of methotrexate and intermittent cyclosporine therapy in extensive chronic plaque psoriasis: A randomized, double-blind, and comparative study. Natl J Physiol Pharm Pharmacol, 13 (12), 2433-2439.

doi:10.5455/njppp.2023.13.04171202312052023

Turabian Style

Das, Suchibrata, Sangita Patra, Saikat Banerjee, and Alok Kumar Roy. 2023. The efficacy and safety of methotrexate and intermittent cyclosporine therapy in extensive chronic plaque psoriasis: A randomized, double-blind, and comparative study. National Journal of Physiology, Pharmacy and Pharmacology, 13 (12), 2433-2439.

doi:10.5455/njppp.2023.13.04171202312052023

Chicago Style

Das, Suchibrata, Sangita Patra, Saikat Banerjee, and Alok Kumar Roy. "The efficacy and safety of methotrexate and intermittent cyclosporine therapy in extensive chronic plaque psoriasis: A randomized, double-blind, and comparative study." National Journal of Physiology, Pharmacy and Pharmacology 13 (2023), 2433-2439.

doi:10.5455/njppp.2023.13.04171202312052023

MLA (The Modern Language Association) Style

doi:10.5455/njppp.2023.13.04171202312052023

APA (American Psychological Association) Style

doi:10.5455/njppp.2023.13.04171202312052023

About National Journal of Physiology, Pharmacy and Pharmacology

Contact Information

How to cite this article